<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941989</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0022562-101</org_study_id>
    <secondary_id>2020-002887-30</secondary_id>
    <secondary_id>246780</secondary_id>
    <nct_id>NCT04941989</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562</brief_title>
  <official_title>A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Subcutaneous HTL0022562 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, randomised, double-blind, first in human, two part, single centre, placebo&#xD;
      controlled, single and multiple ascending dose trial in healthy adult subjects to evaluate&#xD;
      the safety, tolerability and pharmacokinetics of HTL0022562.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first in human, two part, double blind, placebo controlled, randomised single and&#xD;
      multiple ascending subcutaneous dose study to evaluate the safety, tolerability and&#xD;
      pharmacokinetics of HTL0022562.&#xD;
&#xD;
      Part 1 comprises of 7 sequential ascending dosing cohorts and Part 2 comprises of 4 multiple&#xD;
      ascending dosing cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Screening up to post last dose: Day 8 (Part 1) / Day 15 (Part 2)</time_frame>
    <description>All AEs, including clinical laboratory, vitals signs, body temperature, respiratory rate, physical examinations, local tolerability and site injection reactions, and ECGs will be analyzed in all subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Cmax</measure>
    <time_frame>Part 1 up to Day 8, Part 2 up to Day 15</time_frame>
    <description>Plasma pharmacokinetic parameter: maximum systemic concentration of HTL0022562</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Tmax</measure>
    <time_frame>Part 1 up to Day 8, Part 2 up to Day 15</time_frame>
    <description>Plasma pharmacokinetic parameter: time to Cmax of HTL0022562&#xD;
Plasma pharmacokinetic parameter: time to Cmax of HTL0022562</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Area Under Curve (AUC)</measure>
    <time_frame>Part 1 up to Day 8, Part 2 up to Day 15</time_frame>
    <description>Plasma pharmacokinetic parameter: Area under the plasma concentration versus time curve derived from systemic concentrations of HTL0022562</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Ae</measure>
    <time_frame>Part 1 up to Day 8, Part 2 up to Day 15</time_frame>
    <description>Urine pharmacokinetic parameter: Amount of HTL0022562 recovered in urine for each urine collection interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1 Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects in up to 7 cohorts will be dosed. One or more subcutaneous injections of HTL0022562 will be administered. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects in up to 4 cohorts will be dosed, following safety, tolerability and PK review of completed dose of Single Ascending Dose Cohort 5. In each cohort, 6 subjects will receive HTL0022562 and 2 subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0022562</intervention_name>
    <description>HTL0022562</description>
    <arm_group_label>Part 1 Single Ascending Dose</arm_group_label>
    <arm_group_label>Part 2 Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part 1 Single Ascending Dose</arm_group_label>
    <arm_group_label>Part 2 Multiple Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or healthy females (WoNCBP) aged 18 to 55 years inclusive, with a body&#xD;
             mass index 18.5-30kgm2 and body weight less than 50kg.&#xD;
&#xD;
          -  Healthy on the basis of a clinical history, physical examination, electrocardiogram&#xD;
             (ECG), vital signs and laboratory tests of blood and urine.&#xD;
&#xD;
          -  Willingness to comply with requirements or the trial, including contraception&#xD;
             requirements.&#xD;
&#xD;
          -  Able to give fully informed consent.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed current COVID 19 infection before randomisation.&#xD;
&#xD;
          -  Clinical signs and symptoms consistent with COVID 19 (e.g. fever, dry cough, dyspnoea,&#xD;
             sore throat, or fatigue) or confirmed infection by appropriate laboratory test within&#xD;
             the last 4 weeks prior to Screening or on admission.&#xD;
&#xD;
          -  Suffered from severe course of COVID 19 (ECMO, mechanically ventilated).&#xD;
&#xD;
          -  Receipt of any IMP in a clinical research study within the previous 3 months (or 5&#xD;
             half-lives, whichever is longer) of Screening.&#xD;
&#xD;
          -  Any abnormalities on 12-lead ECG or BP at Screening (as specified).&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
          -  Vital signs outside the normal range for healthy volunteers&#xD;
&#xD;
          -  Clinically significant abnormal biochemistry, haematology, coagulation, or urinalysis&#xD;
&#xD;
          -  Abnormal renal function, hepatic function or history of abnormal hepatic function&#xD;
             occurring during treatment with investigational or licensed drugs, which led to&#xD;
             permanent discontinuation of treatment.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV),&#xD;
             or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             or gastrointestinal disease, neurological or psychiatric disorder, or current hepatic&#xD;
             renal dysfunction as judged by the investigator.&#xD;
&#xD;
          -  Risk factor for ischaemic heart disease or cerebrovascular disease.&#xD;
&#xD;
          -  Failure to satisfy, in the Investigator's judgement, the subject's fitness to&#xD;
             participate for any other reason, including previous serious adverse reaction or&#xD;
             serious hypersensitivity reactions to any drug or formulation excipients administered&#xD;
             parenterally or orally.&#xD;
&#xD;
          -  All female subjects must have a negative serum and urine pregnancy test at Screening&#xD;
             and admission, respectively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pablo Forte Soto, MD MSc PhD</last_name>
    <phone>+44 1895 614355</phone>
    <email>Pablo.ForteSoto@parexel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Howe, MBChB MD MRCOG</last_name>
    <phone>+44 1223 949254</phone>
    <email>David.Howe@soseiheptares.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parexel Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in Human</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

